Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: A clinician's perspective

American Journal of Hematology

Volumn 87, Issue 10, 2012, Pages 946-947

  Ruggeri, Marco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; PLACEBO; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR;

BLEEDING; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NOTE; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SPLENECTOMY; STANDARDIZATION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

BENZOATES; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84866746579     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23298     Document Type: Note

References (18)

1. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008; 371: 395-403.
2. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889-1899.
3. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641-648.
4. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
5. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
6. Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8: 1372-1382.
7. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
8. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
9. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; CD008235.
10. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115: 2755-2762.
11. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002; 359: 23-29.
12. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401-1407.
13. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386-2393.
14. Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: Should we revisit the indications? Br J Haematol 2012; 158: 16-29.
15. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.
16. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
17. Patel VL, Mahévas M, Lee SY, et al. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP). Blood 2012; 119: 5989-5995.
18. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118: 4338-4345.